From Medscape Oncology

Coverage from the

Gastrointestinal Cancers Symposium (GICS) 2025

January 23 - 25, 2025; San Francisco, California and Online

January 23 - 25, 2025 San Francisco, California and Online

Conference News

GICS 2025 Is One Cycle of Neoadjuvant Pembro OK in dMMR Colon Cancer?
Medscape Medical News, January 30, 2025
GICS 2025 New Data Support ctDNA-Guided Treatment in CRC
Medscape Medical News, January 29, 2025
GICS 2025 No Benefit with Pamrevlumab in Pancreatic Cancer
Medscape Medical News, January 29, 2025
GICS 2025 No Added Benefit with Adjuvant Chemoradiation in Gallbladder Cancer
Medscape Medical News, January 28, 2025

GICS 2025 Low-Dose Aspirin Cuts CRC Recurrence
Medscape Medical News, January 28, 2025
GICS 2025 Immunotherapy + CRT Boosts Response in Esophageal Cancer
Medscape Medical News, January 27, 2025
GICS 2025 Drug Combo for Common Neuroendocrine Tumor: A New Standard?
Medscape Medical News, January 27, 2025
GICS 2025 Promising New Blood Test for Colorectal Cancer Screening
Medscape Medical News, January 24, 2025

Medscape Oncology©

Popular News From GICS 2024

Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC First-line nivolumab plus ipilimumab led to significantly better 2-year PFS in metastatic CRC than chemotherapy as well as pembrolizumab monotherapy.
Medscape Medical News, Jan 23, 2024
Study Reveals Disparities in CRC Biomarker Testing Trends Testing trends are consistent with guideline recommendations and FDA approvals, but demographic disparities exist.
Medscape Medical News, Feb 01, 2024
Data Support Upfront Radioligand Therapy in High-Grade NETs Some physicians commented, however, that they will reserve 177Lu-DOTATATE in the first line for the most aggressive cases.
Medscape Medical News, Jan 25, 2024

Previous Coverage

All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.